Alector, Inc. (ALEC) — SEC Financial Statements & Analysis

Alector, Inc. (ALEC) is a biological products, (no diagnostic substances) company. Alector, Inc. trades on Nasdaq as: ALEC. Alector, Inc. (ALEC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Alector, Inc. carries a market cap of $223.56M, a P/E ratio of -1.90x, a P/B ratio of -22.42x, a P/S ratio of 16.13x, an enterprise value of $171.65M, and an EV/EBITDA multiple of -1.41x. On profitability, it posts an operating margin of -912.40%, a net margin of -850.13%, a Return on Equity (ROE) of -385.11%, a Return on Assets (ROA) of -42.15%, and a Return on Invested Capital (ROIC) of -194.53%. Per share, it reports EPS of $-1.06, diluted EPS of $-1.06, free cash flow per share of $-1.42, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -82.91% year-over-year, net income growth of 2.22% year-over-year, and EPS growth of -7.75% year-over-year. On the balance sheet, it maintains a current ratio of 5.26x, a quick ratio of 5.05x, working capital of $145.85M, a debt-to-equity ratio of -21.35x, a debt ratio of 1.05, free cash flow of $-158.39M (TTM), and net debt of $-51.91M. Figures sourced from SEC EDGAR.

Market Cap

$223.56M

P/E TTM

-1.90x

EPS TTM

$-1.06

P/B TTM

-22.42x

ROE TTM

-385.11%

ROA TTM

-42.15%

Debt To Equity

-21.35x

Free Cash Flow TTM

$-158.39M

Net Revenue TTM Growth 1Y

-82.91%

Data as of 2026-06-30 · Source: SEC EDGAR